Delivery Order SPE2DB20D2014-SPE2DB25FC22S
- Not listed
- The Defense Logistics Agency awarded a $10,393.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 300 mg/2 mL syringes on July 9, 2025, with completion targeted for July 30, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $4,322.04 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes with a completion date of August 28, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare...
- The Defense Logistics Agency awarded a $3,241.54 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct procurement of pharmaceutical supplies for federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This...
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $4,322.04 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes on July 18, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract is for performance at AmerisourceBergen's corporate headquarters location in...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $8,644.08 by the Defense Department's Medical Supply Chain to deliver XOLAIR 150 mg/mL syringes. The contract, awarded on July 15, 2025, is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and carries no set-aside designation. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, with an ultimate completion date of August 27, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $2,881.36 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of August 25, 2025. This competitive award, issued on August 4, 2025, utilizes firm fixed pricing and carries no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $10,805.10 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be performed at the vendor's Corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,161.02 to AmerisourceBergen Drug Corp for the supply of XOLAIR 150 mg/ml syringes. The award was made on July 24, 2025, with an ultimate completion date of August 14, 2025, under a firm fixed-price delivery order contract type with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and is a major pharmaceutical distributor specializing in...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC22SDelivery Order
The Defense Logistics Agency awarded a $8,644.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes on June 16, 2025, with completion targeted for July 9, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor for military and veteran healthcare systems. The company was competitively awarded this delivery order based on its established capability to fulfill federal pharmaceutical supply requirements through its prime IDC with DLA. The contract will be performed at the company's corporate office location in Conshohocken, PA, with the pharmaceutical product supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 6/16/25 |